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Measuring degranulation through CD107a expression has become an advantageous 
tool for testing the functional capacity of cytotoxic cells. Such functional studies have 
been hampered in the rat by the lack of a suitable anti-rat CD107a antibody. In this 
study, we report a novel hybridoma generated by immunizing Armenian inbred hamsters 
with transfected Chinese hamster ovary cells expressing CD107a. The SIM1 clone 
exhibited specific reactivity with CD107a and measured degranulation from natural killer 
(NK) cells stimulated with target cells or mAb crosslinking of their activating receptors. 
Degranulation in IL-2-activated NK cells could also be measured, when using low effec-
tor to target ratios. SIM1 also stained activated CD8, but not CD4 T cells. This report 
characterizes the degranulation response in cytotoxic rat cells with a new antibody 
against rat CD107a.
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INtRodUCtIoN
Cytotoxic cells are integral in the fight against viral-infected and cancer cells. These cells kill 
through three different pathways, the release of lytic granules, Fas receptor-ligand pathway, or the 
TRAIL–TRAIL receptor pathway. For the purpose of this paper, we will focus on degranulation. 
When a cytotoxic cell encounters a target cell, it adheres tightly to it forming the immune synapse. 
The lytic granules are then polarized toward the immunologic synapse and released from the 
cytotoxic cell directed toward the target (1). These granules contain various cytotoxic mediators 
such as perforin and granzymes. Released perforin can form transient pores within the target cell 
membrane allowing granzymes to enter the target cell. Entry is probably also mediated by perforin 
oligomers forming incomplete pores (arcs) (2), and it has also been suggested that granzymes and 
perforin can be taken up into the target cells through the endosomal pathway (3, 4). The data 
behind these proposed mechanisms have recently been discussed in detail (5). When granzymes 
enter target cells the caspase pathway is activated resulting in apoptosis (6, 7). The membrane of 
these cytotoxic granules contains lysosomal-associated membrane glycoprotein-1 (LAMP1), also 
known as CD107a (8). The luminal part of rat CD107a is transiently exposed to the extracellular 
side of the cell membrane after degranulation before it is again internalized. Therefore, CD107a 
staining indicates that a degranulation event has occurred (9). While the role for CD107a is still 
being determined, siRNA studies against CD107a has shown it is essential for perforin trafficking 
within the vesicles, as delivery of perforin to lytic granules is inhibited in the absence of CD107a 
(10). CD107a has also been shown to have a role in protecting cytotoxic cells from death by binding 
to perforin and preventing insertion into the cell membrane (11).
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There are two main types of cytotoxic lymphocytes, natural 
killer cells (NK) and CD8 T cells. Both cell types kill through the 
release of lytic granules, the Fas receptor/Fas ligand pathway and 
the TRAIL/TRAIL receptor pathway, but the stimulus necessary 
to activate these two cell groups is different. T cells recognize 
antigen presented by MHC class I molecules through their 
activating T cell receptor (TCR), while NK cells recognize target 
cell antigens though various inhibitory and activating receptors. 
Inhibitory receptors are important for preventing NK cells from 
killing healthy cells while activating receptors induce NK cell 
cytotoxicity.
Before the identification of CD107a as a marker for degranu-
lation in NK cells (12), the output for measuring the cytotoxic 
ability was the death of the target cells. Detection of CD107a 
by flow cytometry allowed researchers to identify the specific 
effector cells with cytotoxic ability. Since its discovery, a wide 
array of publications of data from mouse and human studies has 
been completed showing the advantage of using an anti-CD107a 
antibody. The rat is a valuable immunological animal model for 
studying diseases such as leukemia and graft vs. host disease (13), 
but functional readouts have been hampered by the lack of high 
quality specific anti-rat CD107a antibodies for flow cytometry. 
This paper describes the creation of an antibody toward rat 
CD107a and characterization of the degranulation response in 
rat NK and CD8+ T cells.
MAteRIALs ANd Methods
Animals
Armenian inbred hamsters (Cytogen Research and Development 
Inc., MA, USA) were housed in the Department of Comparative 
Medicine at Rikshospitalet, Oslo University Hospital, in agree-
ment with institutional guidelines. The rat strains PVG-RT1U, 
PVG-RT7b, PVG-RT1N, and PVG-R23 were used interchange-
ably and maintained for more than 20 generations and housed 
in compliance with guidelines set by the Experimental Animal 
Board under the Ministry of Agriculture of Norway and by the 
European Convention for the Protection of Vertebrate Animals 
used for Experimental and Other Scientific Purpose. Rats were 
used by the age of 8–12 weeks. The laboratory animal facilities 
are subjected to a routine health-monitoring program and 
tested for infectious organisms according to a modification of 
Federation of European Laboratory Animal Science Association 
recommendations. Animal experiments were regulated through 
laboratory regulations, which are put forth by the Animal Welfare 
act in which Norway follows the EU laboratory direction and the 
European laboratory convention.
Abs and Reagents
Antibodies against NKp46 [Wen23-Pacific Blue (PB) or uncon-
jugated], NKR-P1A 3.2.3-PB, or unconjugated (binding only 
NKR-P1A, but not NKR-P1B, in the PVG strain), CD8 (OX8-
biotin), CD2 (OX34, unconjugated), TCR (R73-Alexa647), 
mouse IgD b allotype (TIB96-unconjugated, used as mouse 
IgG isotype), and CD45.2 (His41-FITC, used as mouse IgG 
isotype) were made in our laboratory and conjugated according 
to standard protocols. Antibodies against CD3 (IF4, uncon-
jugated) and its isotype mouse IgM (MM-30, unconjugated) 
and Armenian hamster IgG isotype control (HTK88-FITC) 
were purchased from Biolegend (San Diego, CA, USA). 
Commercial anti-CD107a antibodies were purchased from 
AbCam (Cambridge, UK) (H4A3-FITC), eBioscience (San 
Diego, CA, USA) (ID48-PerCP-eFluor), and Lifespan (Seattle, 
WA, USA) (LS-C8580-unconjugated). LS-C8580 was conju-
gated with Alexa488 NHS ester (Sigma-Aldrich, St. Louis, MO, 
USA) for use in functional assays. Anti-FLAG antibody (M2, 
unconjugated) and anti-mouse IgG (goat polyclonal-FITC) were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). IL-2 was 
obtained from a dialyzed cell culture supernatant of a Chinese 
hamster ovary (CHO) cell line stably transfected with a rat IL-2 
expression construct. Peridinin Chlorophyll-a Protein (PerCP) 
conjugated streptavidin, FITC hamster IgG polyclonal isotype 
control, FITC mouse IgG1 isotype control (MOPC-FITC), and 
GolgiStop were purchased from BD biosciences (Franklin Lakes, 
NJ, USA). Goat anti-Armenian hamster (polyclonal-FITC) was 
purchased from Jackson Immunoresearch (West Grove, PA, 
USA). Supernatants from hybridomas OX41, CD172a (SIRPα), 
R73 (anti-rat TCRαβ), OX19 (anti-CD5), OX12 (anti-Igκ chain), 
and OX33 (anti-CD45RA) were made in-house. Control hamster 
serum was derived from un-immunized Armenian hamsters.
Cloning of rat Cd107a
Rat CD107a was PCR amplified from cDNA generated from 
PVG rat splenocytes and subcloned into a pMX expression vector 
containing a puromycin resistance gene (a generous gift from Dr. 
Michael R. Daws) (14). CD107 primers were designed based on a 
rat CD107a (LAMP1) cDNA sequence (GenBank: NM_012857). 
Forward primer: 5′-GCCCCAGCACTGTTCGAGGT-3′; Reverse 
primer: 5′-GTTGTTACCGTCCTGTACACACT-3′. An anionic 
trypsin-1 leader peptide (MSALLILALVGAAVA) was used in the 
expression vector, and the original CD107 transmembrane region 
was replaced by a CD8 transmembrane fragment to facilitate high 
surface expression. A FLAG-tag (DYKDDDDK) was ligated to the 
N-terminal of the CD107 protein to make the surface expression 
detectable. All inserted sequences and open reading frame in the 
final chimeric plasmid construct were examined and confirmed 
by Sanger DNA sequencing.
transfecting BWZ.36 Cells with  
pMX-Cd107a Plasmid
293T cells were seeded into a 6-well cell culture plate with 4 ml 
RPMI 1640 medium, transfected with 7.5 μl FuGENE6 reagent 
(Roche, manufacturer’s protocol) and incubated at 37°C with 
5% CO2. The FuGENE6 reagent was pre-diluted with Opti-MEM 
(Gibco) and mixed with 1.5 μg pMX-CD107a plasmid and 1 μg 
pCL-ECO rodent specific retroviral packaging plasmid (Addgene 
#12371). Twenty-four hours after transfection, the supernatant 
was descanted and replaced with RPMI1640 medium with 2% 
FBS and transferred to 32°C for retroviral production. Forty-
eight hours later, the supernatant was harvested and filtered 
with a 0.2-μm Filtropur S filter (Sarstedt) and saved at −80°C for 
retroviral transduction.
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The 105 BWZ.36 cells [Dr. Nilabh Shastri, U.C. Berkeley, CA, 
USA (15)] were seeded per well into a 24-well cell culture plate 
(Corning) and cultured with fresh RPMI1640 medium with 10% 
FBS, overnight. The supernatant was removed and RPMI1640 
containing 10% FBS, 16 μg polybrene (to a final concentration 
8  μg/ml), and 1.5  ml retroviral supernatant was added and 
centrifuged at 32°C at 2400 rpm for 2 h. The cells were then incu-
bated at 32°C for 1 h after which the supernatant was removed 
and replaced with fresh RPMI1640 medium with 10% FBS and 
cultured for 3  days, at 37°C with 5% CO2 (on day 2, complete 
medium with 1  ng/ml puromycin could be used). Expanded 
BWZ.CD107a-FLAG transfectants were examined for surface 
expression of the FLAG-tag and then were used for antibody 
immunization or antibody screening.
Generating Cd107a expressing 
transfectants
The chimeric rat CD107a plasmid was transfected into CHO cells. 
Briefly, CHO cells were cultured in complete RPMI1640 medium 
(cRPMI; RPMI1640 medium with 10% FBS, 1mM Na Pyruvate, 
50μM 2-mercaptoethanol) until they reached 30% confluency. 
The 2.5 μg plasmid was mixed with 7.5 μl of Fugene 6 reagent 
(Roche) [pre-diluted with Opti-MEM® (Gibco)] and added onto 
cells dropwise. Two days following, the CHO cells were detached 
with RPMI1640 medium supplemented with 2mM EDTA and 
were seeded out in 96-well flat bottom cell culture plates (25 cells/
well) with selection medium (cRPMI supplemented with 20 μg/ml 
puromycin) for cloning of stable transfectants. After 10–12 days 
culture, grown-up clones were screened with anti-FLAG antibody 
(M2). One of the clones expressing highest surface level of FLAG 
and CD107a was used for immunizations.
Immunization and Cell Fusion
The 3- to 10-week-old male Armenian inbred hamsters were 
immunized by intraperitoneal injections (i.p.) with 2 × 106 CHO.
CD107a-FLAG cells once a week for 3  weeks. A boost with 
4 × 106 stably transfected BWZ.CD107a-FLAG cells was given i.p. 
32 days after first immunization and the sera were analyzed for 
surface staining of both CHO.CD107a-FLAG and BWZ.CD107a-
FLAG transfectants. Two of the three animals were positive, and 
3 days after boosting, spleen cells were harvested and pooled from 
the two animals, one of which had splenomegaly. About 2.0 × 108 
spleen cells and 1.4 × 108 NS0 myeloma cells were washed three 
times in DMEM with additives (1mM sodium pyruvate, 0.05mM 
2-mercaptoethanol and antibiotic/antimycotic) and centrifuged 
at 90 g for 10 min. Keeping everything at 37°C from this point 
forward, the pellet was dissolved by tapping the tube and pre-
warmed polyethylene glycol 1500 (Roche) was added drop by 
drop while gently stirring for 1 min. Three milliliters of DMEM 
with additives were gradually added for the next 3 min finishing 
with an extra 7  ml before centrifuged at 500  g. The pellet was 
washed by careful flushing (no resuspension) with DMEM with 
additives and 20% FBS (DMEM-20) and cultured overnight. Cells 
were harvested the following day and 100  ml DMEM-20 with 
2× hypoxanthine–aminopterin–thymidine (SIGMA) and 10% 
hybridoma cloning supplement (HCS) (PAA) was added. The 
cell suspension was transferred to 96-well plates. After 12 days, 
supernatants from growing clones were tested by flow cytometry 
for staining of surface antigens present on BWZ.CD107a-FLAG 
and CHO.CD107a-FLAG, but not on BWZ.36 cells transfected 
with irrelevant FLAG-tagged antigens as negative controls. The 9 
of 12 positive clones producing specific antibodies were further 
subcloned using DMEM-20 supplemented with hypoxanthine-
thymidine and HCS. Only one clone (SIM1) still produced anti-
bodies after subcloning and this was further subcloned one more 
time. CD107a specific hamster IgG antibodies were detected by 
FITC anti-Armenian hamster IgG (Jackson Immunoresearch). 
Anti-CD107a from the SIM1 hybridoma was purified by HiTrap 
Protein G HP (GE Healthcare, Life Sciences) and FITC-conjugated 
according to standard procedures or Alexa488-conjugated 
according to manufacturer’s protocol.
Generation of effector Cells
Single cell suspensions were prepared from the spleen. Lympho-
cytes were isolated using a Lymphoprep gradient and then run 
over a nylon wool column to remove B cells and macrophages. For 
generation of IL-2-activated NK cells (LAK), the remaining cells 
were cultured overnight in IL-2. The following day, non-adherent 
cells were removed by washing with PBS and the adherent NK 
cells were maintained in RPMI supplemented with IL-2, 10% 
heat inactivated FBS, 1% Streptomycin/Penicillin, 1mM sodium 
pyruvate, and 50 μM 2-mercaptoethanol. Cells were cultivated 
for 8–10  days. For generation of enriched NK cells or sorted 
T  and NK cells, cells were enriched by negative selection after 
the nylon wool step. For enrichment of NK cells, pan-mouse IgG 
Dynabeads (Invitrogen Dynal) were coated with antibodies against 
macrophages (OX41), T cells (R73 and OX19), and B cells (OX12 
and OX33). For enrichment of T cells, pan-mouse IgG Dynabeads 
were stained with antibodies against macrophages (OX41) and 
B cells (OX12 and OX33). Cells were enriched by two steps of 
negative selection with stained beads for 30 min at 4°C. Enriched 
NK cells had a purity of approximately 50–60% and were used 
for degranulation studies. Enriched T cells (79–85% purity) were 
further sorted for TCR+ cells using a FACS Aria (BD Biosciences).
degranulation Assays
To measure the degranulation response by staining with anti-rat 
CD107a (SIM1) during target cell stimulation, NK effectors and 
YAC targets cells were incubated, at a 1 to 1 ratio of 3 × 105 cell/
well (unless stated otherwise) in media containing the SIM1 
mAb, the other commercially available anti-CD107a antibod-
ies, or isotype control. To measure the degranulation response 
to antibody stimulation from NK cells, we used flat bottom 
96-well plates coated with varying concentrations of anti-NKp46 
(Wen23), anti-NKR-P1A (3.2.3), and a mouse IgG1 isotype 
control (TIB96). The following day, plates were washed with PBS 
and blocked with cRPMI before addition of 3 × 105 enriched NK 
cells suspended in cRPMI containing SIM1 were added per well. 
To measure degranulation from T cells, they were sorted and 
cultured in cRPMI with IL-2 for 2–3 days. The 96-well flat bottom 
plates were coated over night with antibodies against CD3 (IF4), 
CD2 (OX34), or an IgM isotype control (MM-30). About 3 × 105 
T cells were added per well in cRPMI containing SIM1. All assays 
were incubated for 4 h. Golgistop was added for the last 3 h of 
FIGURe 1 | Generation of an anti-rat Cd107a monoclonal antibody (sIM1). (A) Schematic vector map of the pMX expression vector with leader peptide, 
FLAG-tag, CD107a insert, and the transmembrane domain of CD8. (B) Stably transfected Chinese hamster ovary and BWZ.36 cells were tested for cell surface 
expression of FLAG-tagged CD107a using an anti-FLAG antibody (M2) (shaded histograms). Negative control is secondary antibody alone (transparent histogram). 
(C) BWZ cells transfected with CD107a-FLAG or irrelevant antigen (NKR-P1F-FLAG) were stained with hamster control serum, SIM1 supernatant, or an anti-FLAG 
antibody (M2).
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incubation to prevent the degradation of internalized CD107a. 
Cells were then washed and stained with antibodies toward the 
appropriate surface receptors and analyzed using the FACS Canto 
or LSR II (BD Biosciences).
Chromium Release Assay
YAC-1 target cells (5  ×  106  cells/ml cRPMI) with added 3.7 
MBq51Cr were incubated at 37°C for 1 h, stirring every 15 min. 
Cells were then washed three times with PBS with 2% FBS and 
resuspended to 1 × 105 cells/ml in cRPMI. LAK effector cells and 
target cells were plated at the specified ratios in a final volume 
of 200 μl. Cells were centrifuged and incubated for 4 h at 37°C. 
Specific release of 51Cr was measured using the Cobra auto-
gamma (Packard).
ResULts
To create an antibody against CD107a, we made an expression 
vector containing the extracellular membrane region of rat 
CD107a, the transmembrane region of rat CD8, and a 3′-terminal 
FLAG-tag to detect surface expression (Figure 1A). The vector 
was transfected into CHO cells and the BWZ.36 T cell line and 
screened for CD107a expression using an anti-FLAG antibody 
(M2) (Figure  1B). CD107a stably transfected CHO cells were 
injected into Armenian inbred hamsters once a week for 3 weeks 
with a final boost of CD107a stably transfected BWZ cells 3 days 
before fusion with the NS0 myeloma cell line. Supernatants from 
the different clones were tested for specificity toward BWZ.
CD107a-FLAG, but not irrelevant FLAG-tagged BWZ.36 trans-
fectants. One clone, SIM1, was found to bind specifically to the 
CD107a expressing transfectant, but not to the FLAG transfected 
control (Figure 1C).
The clone SIM1 was further tested in functional assays in par-
allel with two commercially available CD107a antibodies, which 
could potentially cross react with rat CD107a in flow cytometry. 
The antibody clones tested were H4A3 from AbCam (which cross 
reacts with human, rat, mouse, and primates in flow cytometry) 
and the antibody clone LS-C8580 from LifeSpan BioSciences 
(which cross reacts with CD107a from mouse, human and rats 
in immunohistochemistry and Western blots according to the 
manufacturer’s website). Our SIM1 antibody clone identified 
degranulating cells in the presence of target cells and showed 
little background staining in the absence of targets (upper panel 
Figure 2A). Clone H4A3 stained the highest percentage of NK 
cells after target cell stimulation (middle panel). However, there 
was also a high level of background staining in the absence of 
target cells, indicating unspecific binding. Very low levels of 
degranulation, if any, were measured by the LS-C8580 mAb clone 
(lower panel). The specificity of these antibodies was confirmed 
by positive staining of the BWZ.CD107a-FLAG transfectant, but 
not BWZ.NKR-P1F-FLAG control (Figure  2B). The antibody 
clone H4A3, which has been shown to bind to human CD107a 
(16), did not stain rat CD107a transfected BWZ cells, indicat-
ing there is no cross reaction with rat CD107a. The anti-mouse 
CD107a clone ID48 also failed to stain the rat CD107a transfect-
ant. Unconjugated LS-C8580, on the other hand, showed specific 
staining of CD107a transfected cells (data not shown). However, 
the LS-C8580 clone is only available as unconjugated antibody 
which is not suited for degranulation studies. Repeated attempts 
in our laboratory to conjugate LS-C8580 to Alexa488 have unfor-
tunately not provided any strong staining conjugates, though the 
small sample size and concentration of LS-C8580 may be the cause 
of the poor conjugation. Conjugated LS-C8580 shows reduced 
but specific staining of CD107a transfected cells (Figure 2B), but 
as shown in Figure 2A, we were not able to detect degranulating 
cells during functional assays with this conjugate. In conclusion, 
the SIM1 mAb specifically stains degranulating rat NK cells after 
stimulation with target cells.
FIGURe 2 | sIM1 measures degranulation from natural killer (NK) and Cd8 t cells. (A) Percent degranulating cells were measured using anti-CD107a 
antibodies SIM1, H4A3, and LS-C8580, with or without YAC-1 target cells as a stimulus. One representative experiment of four is shown (B). Staining of the BWZ.
CD107a-FLAG cell line with SIM1, H4A3, LS-C8580, or ID48 antibody clones. BWZ.36 cells transfected with irrelevant FLAG-tagged antigen (BWZ.NKR-P1G-FLAG) 
was included as a negative control, (C) enriched NK cells were stimulated with plate bound anti-NKp46, anti-NKR-P1A, or mouse IgG1 as isotype control, and SIM1 
was used to measure percentage degranulating cells. NKp46+ (Wen23) or NKR-P1Abright (3.2.3) cells were gated on. (d) TCR+ cells were sorted (purity 99%) and 
cultured in IL-2 for 2–3 days. The cells were then stimulated with plate bound anti-CD3 and anti-CD2 or mouse IgM isotype control for anti-CD3. The lower panel 
shows stimulation with anti-CD3 and anti-CD2 and staining with a SIM1 isotype control (FITC hamster IgG polyclonal). T cells were sorted using R73-Alexa647 and 
3.2.3-PB antibodies, gating on R73+/3.2.3− cells. Data shown are from one representative experiment of three separate independent experiments.
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Direct stimulation of activating NK receptors through 
plate bound antibodies is another potent method to induce 
degranulation. To test the SIM1 clone in this functional 
assay, we incubated enriched NK cells on plates coated with 
antibodies toward the activating receptors NKp46 and NKR-
P1A (Figure  2C). As a negative control, plates were coated 
with mouse IgG1 isotype control. Staining with the SIM1 
antibody identified 25.5 or 44% degranulating cells after NK 
cell stimulation in plates coated with 5 μg/ml anti-NKp46 or 
anti-NKR-P1A respectively. The percentage of degranulating 
cells increased even further when the plates were coated with 
a higher concentration of stimulating antibodies (10  μg/ml). 
No degranulation was induced in wells coated with the mouse 
IgG1 isotype control.
We clearly saw degranulation in NK cells stimulated with 
either target cells or with antibodies against activation receptors 
FIGURe 3 | Low effector:target ratios are important to ensure adequate sensitivity in degranulation assays with rat NK cells. (A) Degranulation of LAK 
cells cultured 8–10 days in IL-2 against YAC-1 targets at different effector:target ratios. (B) Cytotoxicity of IL-2 cultured LAK against YAC-1 target cells was 
confirmed with the chromium release assay completed on days 8–10. All graphs are cumulative of three or more separate experiments with bars showing SD.
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by using our SIM1 antibody. We also wanted to confirm this in 
cytotoxic T cells. T cells were sorted from spleen cells and cul-
tured in IL-2 for 2–3 days. The T cells were then stimulated with 
plate bound anti-CD3 and anti-CD2 (Figure 2D). Degranulation 
was measured from cultured CD8+ T cells when stimulated with 
anti-CD3 and anti-CD2 on both days 2 and 3. No degranulation 
was measured from non-cytotoxic CD4 T cells, or after stimula-
tion with isotype control antibody, further demonstrating the 
specificity of our SIM1 antibody.
Lymphokine-activated killer (LAK) cells are created by cultur-
ing NK cells in IL-2 for 7–10  days and are commonly used as 
very potent effector cells in chromium release assays to study 
cytotoxicity and, therefore, should be able to generate high levels 
of degranulation. To measure degranulation from LAK cells, we 
initially used a 1:1 ratio of effector to targets but found unex-
pectedly low levels of degranulation (data not shown). However, 
doing a titration to find optimal effector to target ratios we saw 
increasing levels of degranulation could be achieved when effec-
tor to target ratios were below 1 (Figure 3A). The optimal ratio 
for degranulation assays is therefore in contrast to cytotoxicity 
assays where the level of cytotoxicity increases with higher effec-
tor: target ratios (Figure 3B).
dIsCUssIoN
In the initial testing of SIM1 and the different commercial 
CD107a antibodies in degranulation assays in the rat, we chose 
a small range of effector to target ratios with a skewing toward 
more effector cells than targets based on current literature (12, 
16, 17). Effector to target cell ratios can vary from paper to paper, 
but previous studies which titrated effector to target ratios have 
shown that optimal degranulation from mouse NK cells peaked 
at 4.5:1 ratio with YAC-1 target cells (18) and human NK cells 
killed K562 cells best at a ratio of 5:1 or 10:1 (12). However, when 
using a larger range of effector to target ratios, we show that 
degranulation using rat LAK cells was more effectively induced 
when using four or more targets per effector cell. This difference 
in optimal effector:target ratio between the rat and other species 
could be due to the type of target cells used, as the human and 
mouse effector to target ratio titrations in the abovementioned 
studies used target cells that originated from the same species. 
The effector cells might be more sensitive to target cells from 
the same species and therefore need fewer target cells to become 
activated. The YAC-1 cell line used in our study is a mouse T cell 
lymphoma, which have been the standard for many years to 
stimulate cytotoxicity from rat NK cells. We cannot exclude that 
using a rat target cell would result in stronger stimulation of the 
NK cells and subsequently fewer target cells might be needed to 
induce degranulation.
It is also clear from this study that the effector to target ratios 
used for cytotoxicity assays do not correlate well with the ratios 
needed to measure optimal degranulation response in the effector 
cells. This is not surprising as the read out for these two assays are 
different, with cytotoxicity measuring the target cell death, and 
degranulation measuring the NK response to targets.
In conclusion, we have raised an antibody against rat CD107a 
(SIM1) and characterized its ability to detect degranulation in 
cytotoxic lymphocytes in the rat. We have shown that SIM1 is 
specific to degranulating cells, and through optimization of 
the degranulation protocol, we have determined that using 
effector:target cell ratios lower than 1:4 ensure optimal stimula-
tion of LAK cells. The development of anti-rat CD107a (SIM1) 
allows better analysis and characterization of the cytotoxic 
responses of rat lymphocytes and will be a valuable tool in the 
many disease models of the rat.
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